Articles Archives - QualityStocks

WednesdayJun 10, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Onco-Innovations is developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response therapy market that is distinct from established PARP inhibitor therapies. Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has…

MondayJun 08, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body. The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food…

MondayJun 08, 2026 9:00 am

Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) Is ‘One to Watch’

Disseminated on behalf of Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) and may include paid advertising. Redwood AI is developing a proprietary AI platform designed to support drug discovery, synthesis planning, and chemical analysis across pharmaceutical, public safety, defense, and industrial-related markets. The company is positioned across multiple large global market opportunities, including pharmaceutical development, defense-related chemical intelligence, AI-assisted drug discovery, and CDMO infrastructure applications. Reactosphere combines synthesis planning, optimization workflows, sourcing intelligence, and chemical analysis capabilities within a single AI-driven platform. Redwood AI is advancing its AI-powered chemistry platform through research collaborations and government-supported initiatives involving organizations including UBC,…

FridayJun 05, 2026 11:15 am

Bitcoin as a Corporate Treasury Asset: How MindWave Innovations Inc. (NYSE American: APUS) Is Redefining Institutional Yield Infrastructure

MindWave Innovations recently advanced its Bitcoin treasury strategy with up to $100M PIPE and activation of 1,000 BTC, accelerating institutional adoption of AI-driven digital asset infrastructure The company operates at the intersection of insured custody, AI yield engines, and board-governed segregated treasury structures These developments reinforce MindWave’s mission: providing institutional-grade treasury infrastructure for the digital asset economy MindWave Innovations (NYSE American: APUS) is strategically positioning itself at the forefront of a structural shift in corporate finance: the transition from static treasury holdings to intelligent, yield-generating digital asset infrastructure. As companies increasingly follow the path pioneered by MicroStrategy and newer institutional adopters, the demand for compliant, secure, and yield-optimized…

FridayJun 05, 2026 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation

OTLC continues to advance its Deciparticle nanomedicine platform, with expanding international development initiatives supporting future therapeutic and commercial opportunities. The company's PDAOAI ecosystem now incorporates 28 million scientific abstracts and is being deployed into real-world pharmaceutical automation applications through TechForce Robotics. The company is leveraging AI, nanomedicine, and automation to accelerate therapies for cancer and rare diseases. Oncotelic Therapeutics (OTCQB: OTLC) is strategically placing itself at the nexus of precision oncology, advanced automation, and artificial intelligence. Through its PDAOAI artificial intelligence ecosystem, Deciparticle(TM) nanomedicine platform, and emerging robotics initiatives, the company is quickly building an integrated technology portfolio built to…

FridayJun 05, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets Growing Need for Non-Invasive Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics is developing AI-powered voice analysis technology designed to detect drug and alcohol impairment from short speech samples. The platform analyzes more than 140 acoustic markers and has been trained on a dataset exceeding 50 million data points. Mining operations in South America represent the company’s initial commercial focus, where workforce safety and high-volume screening requirements create operational challenges. Potential applications extend beyond mining into aviation, construction, law enforcement, call centers, transportation, and mental health settings. The global alcohol and drug testing devices…

FridayJun 05, 2026 9:00 am

Numa Numa Resources Inc. Committed to Advancing Bougainville Infrastructure Alongside Mining Development

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements. Today many mining projects are designed with a wider development mandate, recognizing that infrastructure can generate benefits extending well beyond the life of a mine. Numa Numa Resources has positioned infrastructure development as a central component of its strategy. The company’s infrastructure efforts are occurring alongside agreements with landowners connected to the Panguna resource area. Modern mining projects are no longer judged solely by the minerals they produce. Increasingly, companies are being evaluated on the roads they build, the power systems they create and the long-term economic…

ThursdayJun 04, 2026 11:15 am

Democratizing the Space Economy: How Public Investment Vehicles Are Opening Private Orbital Opportunities

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising. Traditionally, many significant investment opportunities in the space industry were only accessible to venture capital and institutional investors, leaving retail investors unable to participate. However, Planet Ventures Inc. is changing this, as the company provides shareholders with indirect exposure to private space and aerospace companies through a publicly traded investment vehicle. A variety of companies stretch under Planet Ventures’ belt, including areas like software, energy, robotics, emerging applications, and infrastructure. The commercial space economy is entering a new phase of growth. What was once dominated…

ThursdayJun 04, 2026 9:45 am

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Marks Significant Milestone with Ocean Partners UK Ltd. Definitive Gold and Silver Dore Purchase Agreement

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising. ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, just entered into a definitive gold and silver dore purchase agreement with Ocean Partners UK Ltd. Ocean Partners will purchase 100% of ESGold’s dore production, in exchange for a non-dilutive working capital facility of up to C$9 million Delivery of the dore will be made EXW at the Montauban Project Mine site, with Ocean Partners responsible for collection and related logistics The agreement was based on prevailing LBMA…

ThursdayJun 04, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Humanitas collaboration supports Regentis' physician adoption strategy and broader commercial infrastructure across the European market. GelrinC targets a large orthopedic market that currently lacks an approved off-the-shelf regenerative cartilage repair solution. Pivotal FDA enrollment, manufacturing scale-up, physician engagement initiatives and CE Mark status position the company toward multiple potential value-inflection milestones. Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials (NYSE American: RGNT) is approaching that transition with GelrinC(R), its cartilage regeneration platform targeting a large orthopedic market where treatment alternatives continue to involve…

Site Search

Company Search

Category: Articles